) was a big mover last session with shares rising over 12% on the
day. The move came on solid volume too with far more shares
changing hands than in a normal session. This reverses the recent
downtrend of the company as the stock has lost over 11% in the
last five trading sessions.
This pharmaceutical company has seen three negative estimate
revisions in the last 30 days. The Zacks Consensus Estimate has
also moved lower over the same period. This implies trouble down
the road. So make sure to keep an eye on this stock going forward
to see if yesterday's rally can last.
Relypsa currently has a Zacks Rank #4 (Sell) while its
Some better-ranked generic Med-Drug stocks are
Dr. Reddy's Laboratories Ltd.
). While RDY and MNK sport a Zacks Rank #1 (Strong Buy), ACT
holds a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment
Research? Today, you can download
7 Best Stocks for the Next 30 Days
Click to get this free report >>
ACTAVIS PLC (ACT): Free Stock Analysis Report
MALLINCKRODT PL (MNK): Free Stock Analysis
DOCTOR REDDYS (RDY): Free Stock Analysis
RELYPSA INC (RLYP): Free Stock Analysis
To read this article on Zacks.com click here.